Mineralocorticoid receptor antagonists in heart failure with sustained monomorphic ventricular tachycardia: comparative analysis of spironolactone versus eplerenone.@drkarthik2010 @BoopathyCardio @SanjitSJolly @hfaimedia bit.ly/49qoex1

The ideal puncture site can be identified only by echo!!!!! I think that transesophageal or intracardiac #echofirst guidance should become the only way to perform transeptal puncture!

A p-value below the noninferiority threshold is not a free pass. Noninferiority margins need clinical justification, and intention-to-treat and per-protocol analyses should ideally point in the same direction. As DES outcomes continue to improve, noninferiority trials of coronary devices become increasingly fragile.

Coronary microvascular obstruction: the "no-reflow" problem that haunts STEMI care. New ESC clinical consensus on pathophysiology, prevention & management: a must-read. Read more in #EHJ. doi.org/10.1093/eurheartj/eh… #cardiotwitter @ESC_Journals @escardio

What is the best K level that we can keep for our patients with HF? This patient level meta-analysis published in EHJ has answered it as 4.2- 5 mEq/L. @hfai20 @CsiChennai @mvaduganathan @ehj_ed @INDIACCDC @SRIHER_Official @SRMC_official

Today, on International Clinical Trials Day, We are proud to share that the Dig-RHD trial has been published in JAMA. This is the first randomized controlled trial to test a heart failure therapy specifically in patients with rheumatic heart disease a condition that affects more than 40 million people worldwide, overwhelmingly in low- and middle-income countries, yet has long lacked high-quality trial evidence. It was a privilege to contribute to this study as part of the cardiology team at Sri Ramachandra Institute of Higher Education and Research, working alongside investigators from across the country under the leadership of Dr. Ganesan Karthikeyan (AIIMS, New Delhi) @drkarthik2010 . My sincere gratitude to my teachers and mentors who made this opportunity possible. Congratulations to the entire Dig-RHD team on this meaningful step forward for the millions living with rheumatic heart disease. jamanetwork.com/journals/jam… @SRIHER_Official @SRMC_official #InternationalClinicalTrialsDay #Cardiology #RheumaticHeartDisease #ClinicalTrials #JAMA #EvidenceBasedMedicine #HeartFailure #Clinicaltrials #sriher

A Mayo Clinic-developed artificial intelligence (AI) model can help specialists detect pancreatic cancer on routine abdominal CT scans up to three years before clinical diagnosis. It identifies subtle signs of disease before tumors are visible, when curative treatment may still be possible. The findings, published in Gut, mark a milestone in Mayo Clinic's multiyear research effort to enable earlier detection of one of the deadliest cancers. Learn more: mayocl.in/4eippBP

Congratulations to Dr C Narasimhan sir for the Lifetime Achievement Award at the HRS 2026! Richly deserved for having pioneered EP & for inspiring & training so many cardiologists! (Pic courtesy: @greatbong) #cardiotwitter #epeeps

The Little Master ! @sachin_rt

Combined effect of educational attainment and diabetes on 1-year all-cause mortality in heart failure patients: findings from the National Heart Failure Registry, India. @drkarthik2010 @BoopathyCardio @ICMRDELHI @hfai20 @dranulala @drambujroy @DrCNManjunath bit.ly/4vuKHlS

Compilation of LBT’s into a single image for ease. Thank you @drhussnainsadiq for your work.

Listening to DrSS on Calcified lesions is the best of IndiaLive. @ccclivecases @BSCCardiology .Standing hall!!

Finally published: the COBRRA trial, the first randomized head-to-head comparison of major DOACs — something the companies would never have done themselves, as a direct confrontation goes beyond their commercial interests. This was driven by independent investigators. The results somewhat support the idea of apixaban being the “safer” DOAC. That said, the list of study limitations is long, and for me, labeling something as “safe” is not enough — after all, even placebo is “safe” when it comes to bleeding. nejm.org/doi/full/10.1056/NE…

Impact of invasive coronary function testing on management of ANOCA patients and secondary care resource utilisation: insights from a multicentre retrospective study in the UK. @BHIBristol @RUHBath @drkarthik2010 @BoopathyCardio bit.ly/4camSbZ

Left dom LM PCI is found to have more MACE as compared to non Left dom LM PCI .( Large retrospective data ) @EuroInterventio @ESC_Journals @ACCinTouch @SRIHER_Official @CsiChennai @drvenkat2517 @pmanokar @cardiosadha2

Happy to be a part of Annual Progress Review Meeting held at ICMR Headquarters on Jan 20,2026 (Yoga-CaRe HF Trial). We may expect the results of this largest RCT to study the effect of Yoga based Cardiac rehabilitation in patients with HFrEF by the end of this year ! @INDIACCDC @ICMRDELHI @DrDPrabhakaran @drambujroy @DrGJustinPaul1 @SRIHER_Official @SRMC_official

Can small changes in physical activity make a major difference? On the cover, a meta-analysis suggests that 5 extra minutes of moderate physical activity a day is associated with a reduction of up to 6% of all deaths in the least active adults. Read this & more 👉 spkl.io/6010AUxdw

Expansion of stent frame is a predictor for valve deterioration. @ParasuramMD @sunnygoelmd @CsiChennai @SRIHER_Official @RameshDaggubati